6 results about "Chlamydia trachomatis" patented technology

The invention relates to the technical field of molecular biology, and discloses an LAMP (loop-mediated isothermal amplification) primer group and a kit for detecting three items (Uu, CT and NG) of venereal diseases. The LAMP primer group disclosed by the invention comprises a first primer group for targeting a ureaplasma urealyticum UreB gene, a second primer group for targeting a chlamydia trachomatis gyrA gene and a third primer group for targeting a gonococcus glnA gene. The LAMP primer group provided by the invention has good thermal stability, is suitable for an LAMP amplification detection system at a high temperature of 70 DEG C, reduces non-specific binding, and has good detection sensitivity and specificity. The LAMP primer group and the kit provided by the invention provide an innovative solution for accurate diagnosis of sexually transmitted diseases.

The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

The application belongs to the technical field of biological detection and identification, and discloses a fluorescence PCR probe method detection kit for chameesiphanes grayanus, which comprises a pair of specific fluorescence primers CADQF and CADQR, a probe CADQP, a real-time fluorescence reaction mixture of 2xPremix Ex TaqTM PCR and ROXII, a positive control, a negative control and nuclease-free water; the sequence of the specific fluorescence primer CADQF is SEQ ID NO:1; and the sequence of the specific fluorescence primer CADQR is SEQ ID NO:2. The fluorescence PCR probe method detection kit can quickly and efficiently determine whether the sample to be tested is chameesiphanes grayanus, and can determine the type and content of raw materials in products that cannot be determined from morphology or use chameesiphanes grayanus as raw materials through the fluorescence PCR probe method, thereby providing a more convenient and efficient method for commodity quality and marine sample ecology.

The invention discloses a cervical cancer plasma circulating microbial marker combination, a reagent, a kit, a risk assessment model and application thereof, and belongs to the cross technical field of liquid biopsy and microbiomics. The cervical cancer plasma circulating microbial marker combination disclosed by the invention is prepared from prevotella, stenosiella, chlamydia trachomatis, peptostreptococcus, fusobacterium, campylobacter and haemophilus. Cervical cancer patients and healthy people are verified by using the cervical cancer plasma circulating microbial marker combination disclosed by the invention, the AUC value is 0.939, the sensitivity is 81.58%, the specificity is 90.00%, the accuracy is 85.29%, the positive predictive value is 91.18%, and the negative predictive value is 79.41%, so that the cervical cancer plasma circulating microbial marker combination disclosed by the invention can be used for effectively distinguishing the cervical cancer patients from the healthy people; the method is suitable for early screening of cervical cancer and has remarkable clinical screening application value.

The application discloses a cervical cancer plasma circulating microbial marker combination, a reagent, a kit, a risk assessment model and application thereof, and belongs to the technical field of liquid biopsy and microbiome. The cervical cancer plasma circulating microbial marker combination comprises Prevotella, Sneathia, Chlamydia trachomatis, Peptostreptococcus, Fusobacterium, Campylobacter and Haemophilus. The cervical cancer plasma circulating microbial marker combination is used for verifying cervical cancer patients and healthy people, and the AUC value is 0.939, the sensitivity is 81.58%, the specificity is 90.00%, the accuracy is 85.29%, the positive predictive value is 91.18%, and the negative predictive value is 79.41%, which indicates that the cervical cancer plasma circulating microbial marker combination can effectively distinguish cervical cancer patients from healthy people, is suitable for early screening of cervical cancer, and has significant clinical screening application value.